{"id":8362,"date":"2025-08-01T18:56:57","date_gmt":"2025-08-01T16:56:57","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/"},"modified":"2025-08-01T18:56:58","modified_gmt":"2025-08-01T16:56:58","slug":"rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/","title":{"rendered":"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite"},"content":{"rendered":"<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2025\/rituximab-not-superior.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/2025\/rituximab-not-superior.jpg\" data-sub-html=\"\">\n<figure class=\"article-img\">\n<\/figure><\/div>\n<\/div>\n<p>Pour les patients atteints de granulomatose \u00e9osinophile avec polyangiite (EGPA), le rituximab n&rsquo;est pas sup\u00e9rieur \u00e0 la strat\u00e9gie d&rsquo;induction de r\u00e9mission conventionnelle, selon une \u00e9tude publi\u00e9e en ligne le 29 juillet dans le <i>Annales de m\u00e9decine interne<\/i>.<\/p>\n<p>Benjamin Terrier, MD, Ph.D., de H\u00f4pital Cochin \u00e0 Paris, et ses coll\u00e8gues ont compar\u00e9 le rituximab \u00e0 une strat\u00e9gie conventionnelle pour l&rsquo;induction de la r\u00e9mission chez les patients atteints d&rsquo;EGPA dans un essai de sup\u00e9riorit\u00e9 multicentrique de phase 3. Les patients avec un diagnostic d&rsquo;EGPA, une maladie nouvellement diagnostiqu\u00e9e ou rechute au moment du d\u00e9pistage, ont \u00e9t\u00e9 inclus et assign\u00e9s au hasard de mani\u00e8re en double aveugle pour recevoir des glucocortico\u00efdes plus le rituximab par rapport \u00e0 la strat\u00e9gie conventionnelle des glucocortico\u00efdes seuls ou en combinaison avec le cyclophosphamide sous des formes s\u00e9v\u00e8res. Le crit\u00e8re d&rsquo;\u00e9valuation principal \u00e9tait la r\u00e9mission, d\u00e9finie comme un score d&rsquo;activit\u00e9 de vascularite de Birmingham de 0 et une dose de prednisone de 7,5 mg \/ jour ou moins au jour 180.<\/p>\n<p>Cent cinq participants ont \u00e9t\u00e9 assign\u00e9s au hasard. Les chercheurs ont constat\u00e9 que 63,5% et 60,4% des patients des groupes de rituximab et de contr\u00f4le, respectivement, ont atteint le crit\u00e8re d&rsquo;\u00e9valuation principal (risque relatif, 1,05; intervalle de confiance \u00e0 95%, 0,78 \u00e0 1,42; p = 0,75).<\/p>\n<p>Des r\u00e9sultats similaires ont \u00e9t\u00e9 observ\u00e9s au jour 360. La dur\u00e9e moyenne de la r\u00e9mission \u00e9tait de 48,5 \u00b1 6,51 et 49,1 \u00b1 7,42 semaines dans les groupes de strat\u00e9gie du rituximab et conventionnels, respectivement (p = 0,41). La dose quotidienne moyenne des glucocortico\u00efdes ne diff\u00e9rait pas significativement entre les groupes de traitement, ni une diff\u00e9rence significative dans les taux d&rsquo;\u00e9v\u00e9nements ind\u00e9sirables.<\/p>\n<p>\u00ab\u00a0Sur la base des r\u00e9sultats de cet essai, le r\u00f4le du rituximab dans la gestion th\u00e9rapeutique de l&rsquo;EGPA a \u00e9t\u00e9 mis \u00e0 jour\u00a0\u00bb, \u00e9crivent les auteurs.<\/p>\n<p>                                        <!-- print only --><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pour les patients atteints de granulomatose \u00e9osinophile avec polyangiite (EGPA), le rituximab n&rsquo;est pas sup\u00e9rieur<\/p>\n","protected":false},"author":1,"featured_media":8363,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[313,1829,6187,6186,359,6188,8,6185,650,5393],"class_list":["post-8362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-avec","tag-conventionnelle","tag-eosinophile","tag-granulomatose","tag-pas","tag-polyangiite","tag-pour","tag-rituximab","tag-strategie","tag-superieur","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"Pour les patients atteints de granulomatose \u00e9osinophile avec polyangiite (EGPA), le rituximab n&rsquo;est pas sup\u00e9rieur\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-01T16:56:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-01T16:56:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754067417_Rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"725\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite\",\"datePublished\":\"2025-08-01T16:56:57+00:00\",\"dateModified\":\"2025-08-01T16:56:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/\"},\"wordCount\":331,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754067417_Rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose.jpg\",\"keywords\":[\"avec\",\"conventionnelle\",\"\u00e9osinophile\",\"granulomatose\",\"pas\",\"polyangiite\",\"pour\",\"Rituximab\",\"strat\u00e9gie\",\"sup\u00e9rieur\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/\",\"name\":\"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754067417_Rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose.jpg\",\"datePublished\":\"2025-08-01T16:56:57+00:00\",\"dateModified\":\"2025-08-01T16:56:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754067417_Rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754067417_Rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose.jpg\",\"width\":1280,\"height\":725,\"caption\":\"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/","og_locale":"fr_FR","og_type":"article","og_title":"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite - RVH-Synergie.org","og_description":"Pour les patients atteints de granulomatose \u00e9osinophile avec polyangiite (EGPA), le rituximab n&rsquo;est pas sup\u00e9rieur","og_url":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/","og_site_name":"RVH-Synergie","article_published_time":"2025-08-01T16:56:57+00:00","article_modified_time":"2025-08-01T16:56:58+00:00","og_image":[{"width":1280,"height":725,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754067417_Rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite","datePublished":"2025-08-01T16:56:57+00:00","dateModified":"2025-08-01T16:56:58+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/"},"wordCount":331,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754067417_Rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose.jpg","keywords":["avec","conventionnelle","\u00e9osinophile","granulomatose","pas","polyangiite","pour","Rituximab","strat\u00e9gie","sup\u00e9rieur"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/","url":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/","name":"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754067417_Rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose.jpg","datePublished":"2025-08-01T16:56:57+00:00","dateModified":"2025-08-01T16:56:58+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754067417_Rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754067417_Rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose.jpg","width":1280,"height":725,"caption":"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/rituximab-pas-superieur-a-la-strategie-conventionnelle-pour-la-granulomatose-eosinophile-avec-la-polyangiite\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"Rituximab pas sup\u00e9rieur \u00e0 la strat\u00e9gie conventionnelle pour la granulomatose \u00e9osinophile avec la polyangiite"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/8362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=8362"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/8362\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/8363"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=8362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=8362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=8362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}